



LEI: 549300Q7EXQQH6KF7Z84

13 June 2024

**RTW Biotech Opportunities Ltd**

**Positive Clinical Data Announcement by Largest Portfolio Holding - Avidity Biosciences**

- *Avidity Biosciences announced "unprecedented" AOC 1020 data from Phase 1/2 clinical trial*
- *Avidity plans to accelerate its registrational plans*

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement on 12<sup>th</sup> June by its largest portfolio holding, Avidity Biosciences Inc. ("Avidity") (Nasdaq: RNA) of positive initial data from its Phase 1/2 trial of AOC 1020, an investigational therapy that targets DUX4, the root cause of facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 demonstrated unprecedented and consistent reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favourable safety and tolerability in people living with FSHD. Avidity plans to accelerate initiation of registrational cohorts in its Phase 1/2 trial.

FSHD is a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability, for which there are currently no approved therapies. AOC 1020 is the first investigational therapy designed to treat the underlying cause of FSHD.

As of the most recently published 30<sup>th</sup> April NAV, Avidity represented a 13.4% position.

**Rod Wong, Chief Investment Officer at the Investment Manager, said,**

"We are delighted to have supported Avidity from its crossover round in 2020 all the way through to now this data, which further validates its antibody oligonucleotide conjugate platform. The approach combines 'the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to hit targets traditionally deemed unreachable.'"

The full text of the announcement can be accessed on Avidity's website <https://aviditybiosciences.com/>

**For Further Information:**

**RTW Investments, LP**

Woody Stileman, Managing Director, Business Development  
Krisha McCune, Director, Investor Relations

**+44 20 7959 6361**

[biotechopportunities@rtwfunds.com](mailto:biotechopportunities@rtwfunds.com)

**Buchanan (PR & Communications Adviser)**

Charles Ryland  
Henry Wilson  
George Beale

**+44 20 7466 5107**

**Deutsche Numis (Joint Corporate Broker)**

Freddie Barnfield  
Nathan Brown  
Euan Brown

**+44 20 7260 1000**

**BofA Securities (Joint Corporate Broker)**

Edward Peel  
Alex Penney

**+44 20 7628 1000**

**Cadarn Capital (Distribution & IR Partner)**

David Harris

**+44 73 6888 3211**

**Elxium Fund Management Limited**

**+44 11 8181 0100**

RTW Biotech Fund Management Limited  
Joanna Duquemin Nicolle, Chief Executive Officer  
Sadie Morrison, Managing Director

Tel: +1 914 225 8885

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

**About Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

\*\*\*\*\*

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

\*\*\*\*\*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFIARIIFLIS